Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE The effect of allergy on survival was significant (p = 0.025, HR 0.525, 95% CI 0.299-0.924), independent of the effect of chromosome 1p (p < 0.001, HR 93.4, 95% CI 16-546) and 19q (p = 0.801, HR 1.2, 95% CI 0.23-6.9) codeletion or TP53 mutation (p = 0.015, HR 2.7, 95% CI 1.2-5.9), unrelated to TERT expression (p = 0.365, HR 1.1, 95% CI 0.89-1.4) or ATRX mutation (p = 0.904, HR 1.04, 95% CI 0.51-2.14), independent of tumor grade (grade 2 versus grade 3, p = 0.004, HR 2.2, 95% CI 1.3-3.8), not independent of histology (oligodendroglioma and oligoastrocytoma, NOS versus astrocytoma, p = 0.08, HR 0.62, 95% CI 0.36-1.1). 30611004 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE LGGs are further divided into isocitrate dehydrogenase (IDH) wild type or mutant, which is further classified into either oligodendroglioma that harbors 1p/19q codeletion or diffuse astrocytoma that has an intact 1p/19q loci but enriched for ATRX loss and TP53 mutation. 28392842 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 Biomarker disease BEFREE Importantly, IDH and TERTp co-occurred in 75% of 1p/19q intact, TP53 wild-type oligodendrogliomas, highlighting the potential of the co-mutations in assisting diagnosis of oligodendrogliomas in tumors with clear cell morphology and non-codeleted 1p/19q status. 27556304 2016
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE It was more frequent in astrocytomas and oligoastrocytomas (98/256, 38%) than oligodendrogliomas (28/327, 8.6%; p < .0001) or glioblastoma multiforme (30/210, 14.3%; p < .0001), tightly associated with TP53 mutation (69/71 vs. 20/79; p = 2 × 10(-16)), and mutually exclusive with 1p19q codeletion (1/156 vs. 249/556; p < .0001). 27401888 2016
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 AlteredExpression disease BEFREE Thus, we analyzed the expression of p-CREB in a series of astrocytomas and oligodendrogliomas of different histologic grades by immunohistochemistry and Western blot analysis. p53 overexpression and the Ki-67 labeling index were also assessed in all the tumors. p-CREB immunohistochemical expression was present in 100% of the astrocytic tumors, but in only 46% of oligodendrogliomas (P = .0033 for grade II; P = .0041 for grade III tumors). 25476123 2015
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 AlteredExpression disease BEFREE We analyzed markers, including IDH mutation(IDHmut), 1p19q codeletion(1p19qcodel), ATRX expression loss(ATRX loss) and p53 overexpression, and outcomes in 159 patients with WHO grade II oligodendroglioma, oligoastrocytoma, and astrocytoma (2003-2012). 26210286 2015
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 AlteredExpression disease BEFREE We show here that parkin levels inversely correlate to brain tumor grade and p53 levels in oligodendrogliomas, mixed gliomas and glioblastomas. 23644658 2014
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE All xenograft-producing gliomas harbored "lineage-defining" mutations in CIC (oligodendroglioma) or TP53 (astrocytoma), and 6 of 8 additionally had activating mutations in PIK3CA or amplification of PDGFRA, MET, or N-MYC. 24714777 2014
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 AlteredExpression disease BEFREE We found that oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) at frequencies similar to pure astrocytic tumors, suggesting that oligoastrocytomas and astrocytomas may represent a single genetic or biological entity. p53 protein expression correlated with mutation status and showed significant increases in astrocytomas and oligoastrocytomas compared to oligodendrogliomas, a finding that also may facilitate accurate classification. 25257301 2014
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE Those tumors that lacked LOH 1p19q showed a high frequency of IDH1 mutations and loss of alpha thalassemia/mental retardation syndrome X-linked gene (ATRX) immunoreactivity, indicating a possible phenotypic convergence of true oligodendrogliomas and gliomas of the alternative lengthening of telomeres (ALT) pathway. p53 alterations were common irrespective of the 1p19q status. 24444336 2014
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE In stratified analyses by ethnicity, source of controls, and glioma subtypes, the p53 codon 72 Arg/Pro polymorphism did not alter the risk for glioma in population-based, hospital-based, astrocytoma, and oligodendroglioma studies among Caucasian. 23860773 2013
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE Recently, mutations in IDH1 and IDH2 have been reported as an early and common genetic alteration in diffuse gliomas, being possibly followed by 1p/19q loss in oligodendrogliomas and TP53 mutations in astrocytomas. 21481010 2012
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE In our samples, ATRX mutation was entirely restricted to IDH-mutant tumors, closely correlated with TP53 mutation and astrocytic differentiation, and mutually exclusive with 1p/19q codeletion, the molecular hallmark of oligodendroglioma. 23104868 2012
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE TP53 mutations and 1p19q codeletion are the main molecular abnormalities recorded, respectively, in astrocytomas and oligodendrogliomas and in mixed gliomas. 22890969 2012
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE Moreover two additional genetic alterations are recorded in grade II and III gliomas: TP53 mutations that characterize astrocytomas and 1p19q codeletion (as the result of t(1;19)(q10;p10) translocation) recorded in oligodendrogliomas. 21889777 2011
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 Biomarker disease BEFREE Detection of chromosome 1p/19q status combined with p53 protein immunohistochemistry might be beneficial to improve the pathological diagnosis and to determine the prognosis of patients with oligodendrogliomas. 22166632 2010
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 AlteredExpression disease BEFREE None of the astrocytomas including two pediatric cases showed this alteration (P < 0.05). p53 was expressed in 57.1% of astrocytomas (8/14), 33% of mixed oligoastrocytomas (3/9) and 10% of oligodendrogliomas (2/20). 19934553 2010
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE IDH1 mutations were co-present with TP53 mutations in 63% of low-grade diffuse astrocytomas and with loss of heterozygosity 1p/19q in 64% of oligodendrogliomas; they were rare in pilocytic astrocytomas (10%) and primary glioblastomas (5%) and absent in ependymomas. 19246647 2009
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 AlteredExpression disease BEFREE Combined loss of 1p and 19q was found in 38 of 56 (67.9%) and exhibited distinct concomitant deletion (P = 0.000). p53 overexpression was observed in 17 cases (30.3%), GFAP expression in 18 cases (32.1%), and p16 loss in 40 cases (74%) of oligodendrogliomas. 17319279 2007
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 AlteredExpression disease BEFREE The markers p53 and MIB-1 were significantly higher expressed in astrocytomas than in oligodendrogliomas and expression levels of p53 and EGFR were inversely associated within the astrocytic group. 17390041 2007
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE Our previous and present data show alterations of at least one of TP53 promoter methylation, p14ARF promoter methylation, and TP53 mutations in 43/49 (88%) of low-grade astrocytomas, 15/18 (83%) of oligoastrocytomas, and 35/42 (83%) oligodendrogliomas, suggesting that disruption of the TP53/p14ARF pathway is frequent in all histological types of low-grade glioma. 16025287 2005
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE LOH 1p/19q typically occurred in tumors without TP53 mutations and were most frequent in oligodendrogliomas (69%), followed by oligoastrocytomas (45%), but were rare in fibrillary astrocytomas (7%) and absent in gemistocytic astrocytomas. 15977639 2005
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 Biomarker disease BEFREE The authors performed a retrospective analysis of 1p, 19q, 9p21, TP53, and MGMT status in 46 patients with oligodendrogliomas to address any relations that may exist among these markers with regard to progression-free survival (PFS) and total survival. 16116609 2005
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE We carried out gene expression profiling on 17 oligodendrogliomas (93% with LOH 1p and/or 19q) and 15 low-grade astrocytomas (71% with a TP53 mutation), using a cDNA array containing 1176 cancer-related genes. 15208679 2004
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 GeneticVariation disease BEFREE DNA sequencing, performed in 84% of cases, revealed that TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but were infrequent (13%) in oligodendrogliomas. 15118874 2004